Crystalvue Medical Corporation (TPEX:6527)
Taiwan · Delayed Price · Currency is TWD 66.50
-0.50 (-0.75%)
Jul 30, 2026, 1:30 PM CST
Crystalvue Medical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,698 | 1,929 | 2,152 | 2,190 | 1,241 | 1,144 | |
Market Cap Growth | -22.99% | -10.37% | -1.77% | 76.51% | 8.45% | -3.52% |
Enterprise Value | 1,598 | 1,836 | 1,898 | 2,009 | 1,092 | 1,121 |
Last Close Price | 67.00 | 72.97 | 79.34 | 79.13 | 44.25 | 39.05 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.01 | 13.12 | 16.92 | 21.18 | 10.79 | 14.82 |
Forward PE | - | 15.14 | 15.14 | 16.26 | 8.26 | 8.26 |
PS Ratio | 1.86 | 2.03 | 2.48 | 2.66 | 1.56 | 1.59 |
PB Ratio | 1.72 | 1.88 | 2.29 | 2.56 | 1.60 | 1.59 |
P/TBV Ratio | 1.72 | 1.88 | 2.30 | 2.57 | 1.60 | 1.59 |
P/FCF Ratio | - | - | 95.13 | 14.64 | 28.05 | - |
P/OCF Ratio | 10.01 | 13.86 | 14.06 | 14.22 | 23.97 | 18.09 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.75 | 1.93 | 2.19 | 2.44 | 1.37 | 1.55 |
EV/EBITDA Ratio | 8.51 | 9.65 | 11.45 | 14.40 | 7.59 | 9.15 |
EV/EBIT Ratio | 9.14 | 10.15 | 13.09 | 17.07 | 8.75 | 12.67 |
EV/FCF Ratio | - | - | 83.93 | 13.42 | 24.69 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 |
Debt / EBITDA Ratio | 0.05 | 0.06 | 0.11 | 0.17 | 0.21 | 0.29 |
Debt / FCF Ratio | - | - | 0.82 | 0.17 | 0.71 | - |
Net Debt / Equity Ratio | -0.10 | -0.12 | -0.24 | -0.29 | -0.19 | -0.22 |
Net Debt / EBITDA Ratio | -0.55 | -0.63 | -1.35 | -1.78 | -1.01 | -1.27 |
Net Debt / FCF Ratio | 1.52 | 2.68 | -9.87 | -1.66 | -3.28 | 0.54 |
Asset Turnover | 0.72 | 0.77 | 0.77 | 0.79 | 0.82 | 0.79 |
Inventory Turnover | 1.91 | 2.40 | 2.08 | 2.05 | 2.36 | 2.88 |
Quick Ratio | 0.76 | 1.44 | 1.84 | 1.97 | 1.62 | 1.62 |
Current Ratio | 1.75 | 2.45 | 3.00 | 3.46 | 2.90 | 2.75 |
Return on Equity (ROE) | 15.09% | 14.94% | 14.16% | 12.67% | 15.39% | 11.08% |
Return on Assets (ROA) | 8.61% | 9.12% | 8.01% | 7.03% | 7.99% | 6.06% |
Return on Invested Capital (ROIC) | 16.14% | 18.30% | 17.47% | 16.40% | 16.89% | 15.12% |
Return on Capital Employed (ROCE) | 17.60% | 17.50% | 15.20% | 13.40% | 15.50% | 11.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.47% | 7.62% | 5.91% | 4.72% | 9.27% | 6.75% |
FCF Yield | -3.89% | -2.33% | 1.05% | 6.83% | 3.56% | -25.16% |
Dividend Yield | 4.23% | 3.97% | 2.84% | 2.62% | 5.17% | 4.73% |
Payout Ratio | 39.63% | 38.79% | 41.13% | 54.90% | 40.25% | 43.26% |
Buyback Yield / Dilution | -0.16% | -0.30% | -1.64% | 0.91% | -0.53% | 0.99% |
Total Shareholder Return | 4.07% | 3.67% | 1.20% | 3.52% | 4.63% | 5.72% |